Ionis Pharmaceuticals
IONS
282 hedge funds and large institutions have $2.54B invested in Ionis Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 113 increasing their positions, 70 reducing their positions, and 62 closing their positions.
72% more call options, than puts
Call options by funds: $71.1M | Put options by funds: $41.2M
61% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 70
10% less funds holding
Funds holding: 314 → 282 (-32)
40% less capital invested
Capital invested by funds: $4.23B → $2.54B (-$1.68B)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
47% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 62
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$47.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$39M |
| 3 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$30.9M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$27.4M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
+$27.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$43.7M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$31.3M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$22.2M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$17.5M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$16M |
IONS Hedge Fund Activity: Q2 2016 in Review
282 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q2 2016, worth a combined $2.54B — down 40% from $4.23B a quarter earlier.
Sellers outnumbered buyers: 62 funds closed out of IONS and 33 opened new positions — a net loss of 29 holders — while 70 trimmed existing stakes and 113 added.
The largest buyer was AQR Capital Management, adding an estimated $47.3M. The largest seller was Millennium Management, exiting entirely with an estimated $43.7M sold.
- 282 institutional investors held Ionis Pharmaceuticals (IONS) as of Q2 2016, down from 314 in Q1 2016.
- Funds reported $2.54B of Ionis Pharmaceuticals stock for Q2 2016, down 40% quarter-over-quarter.
- 33 funds opened new Ionis Pharmaceuticals positions in Q2 2016 and 62 closed out, a net change of -29 holders.
- The largest Ionis Pharmaceuticals buyer in Q2 2016 was AQR Capital Management, an estimated $47.3M added.
- The largest Ionis Pharmaceuticals seller in Q2 2016 was Millennium Management, an estimated $43.7M sold.
Based on aggregated 13F filings for Q2 2016.